FDA approves quarterly siRNA for myasthenia gravis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves quarterly siRNA for myasthenia gravis

  • By

  • Mouj Hijazi

  • November 19, 2026

  • 2 min

Share

  • 1

    The FDA approved cemdisiran, the first siRNA therapy for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.

  • 2

    Cemdisiran targets messenger RNA encoding complement component 5 and is administered subcutaneously at 567 mg every 3 months by a health care provider.

  • 3

    In the phase 3 NIMBLE trial, cemdisiran improved MG-ADL scores by 4.5 points at week 24, compared with 2.2 points with placebo.

  • 4

    Cemdisiran improved QMG scores by 4.2 points at week 24, compared with 1.5 points with placebo.

  • 5

    Cemdisiran carries a boxed warning for serious meningococcal infections and is available only through a restricted Risk Evaluation and Mitigation Strategy program.

Original Source(s)

Related Content